BIIB BIOGEN INC.

Nasdaq biogen.com


$ 154.25 $ 4.66 (3.11 %)    

Friday, 31-Oct-2025 18:52:39 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 154.27
$ 147.99
$ 151.20 x 1
$ 155.30 x 25
$ 146.52 - $ 155.18
$ 110.04 - $ 179.20
2,235,290
na
22.63B
$ 0.59
$ 14.07
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 04-24-2024 03-31-2024 10-Q
8 02-14-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 07-25-2023 06-30-2023 10-Q
11 04-25-2023 03-31-2023 10-Q
12 02-15-2023 12-31-2022 10-K
13 10-25-2022 09-30-2022 10-Q
14 07-20-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-03-2022 12-31-2021 10-K
17 10-20-2021 09-30-2021 10-Q
18 07-22-2021 06-30-2021 10-Q
19 04-22-2021 03-31-2021 10-Q
20 02-03-2021 12-31-2020 10-K
21 10-21-2020 09-30-2020 10-Q
22 07-22-2020 06-30-2020 10-Q
23 04-23-2020 03-31-2020 10-Q
24 02-06-2020 12-31-2019 10-K
25 10-22-2019 09-30-2019 10-Q
26 07-24-2019 06-30-2019 10-Q
27 04-24-2019 03-31-2019 10-Q
28 02-06-2019 12-31-2018 10-K
29 10-23-2018 09-30-2018 10-Q
30 07-24-2018 06-30-2018 10-Q
31 04-24-2018 03-31-2018 10-Q
32 02-01-2018 12-31-2017 10-K
33 10-24-2017 09-30-2017 10-Q
34 07-25-2017 06-30-2017 10-Q
35 04-25-2017 03-31-2017 10-Q
36 02-02-2017 12-31-2016 10-K
37 10-26-2016 09-30-2016 10-Q
38 07-21-2016 06-30-2016 10-Q
39 04-21-2016 03-31-2016 10-Q
40 02-03-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-biogen-lowers-price-target-to-210

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $217 to...

 biogen-lowers-fy2025-adj-eps-guidance-from-1550-1600-to-1450-1500-vs-1580-est-sees-sales-9676b-9773b-vs-9686b-est

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. sees sales ...

 biogen-lowers-fy2025-adj-eps-guidance-from-1550-1600-to-1450-1500-vs-1580-est

Biogen (NASDAQ:BIIB) lowers FY2025 Adj EPS guidance from $15.50-$16.00 to $14.50-$15.00 vs $15.80 analyst estimate. Increased e...

 biogen-q3-adj-eps-481-beats-388-estimate-sales-2534b-beat-2339b-estimate

Biogen (NASDAQ:BIIB) reported quarterly earnings of $4.81 per share which beat the analyst consensus estimate of $3.88 by 23.91...

 biogens-immunology-pipeline-has-long-term-potential-analyst

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across mul...

 biogen-to-present-data-from-trials-evaluating-dapirolizumab-pegol-at-american-college-of-rheumatology-convergence-2025-in-chicago

Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc...

 small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

 biogen-says-estimated-charge-expected-to-impact-gaap--non-gaap-net-income-per-diluted-share-for-q3-by-001-per-share-expects-q3-results-to-include-acquired-in-process-rd-upfront-and-milestone-expense-of-about-2m-on-pre-tax-basis

- SEC Filing

 morgan-stanley-maintains-equal-weight-on-biogen-raises-price-target-to-149

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from ...

Core News & Articles

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...

 eisai-and-biogen-announce-lecanemab-irmb-subcutaneous-injection-is-now-available-in-us-as-maintenance-dosing-regimen-for-ad-treatment

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nu...

 nasdaq-100-top-25000-as-amd-spikes-gold-eyes-4000-whats-moving-markets-monday

Tech and AI-related stocks continued to propel Wall Street to new record highs Monday, with Advanced Micro Devices Inc. (NASDAQ...

 trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION